Viking Therapeutics, Inc. (FRA:1VT)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.11B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -202.33M |
| Shares Out | n/a |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 241 |
| Open | 29.81 |
| Previous Close | 31.56 |
| Day's Range | 29.81 - 29.81 |
| 52-Week Range | 16.40 - 42.00 |
| Beta | n/a |
| RSI | 42.14 |
| Earnings Date | Feb 5, 2026 |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ... [Read more]
News
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
Viking Therapeutics remains a massive deal compared to the Metsera buyout, and key Phase 3 trials should provide a major catalyst in 2026. See why VKTX stock is a Buy.
2 Beaten-Down Stocks That Could Bounce Back in 2026
Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges.
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited ...
Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The managem...
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Viking Therapeutics (NASDAQ: VKTX) has outperformed the market over the past 5 years by 32.8% on an annualized basis producing an average annual return of 46.0%. Currently, Viking Therapeutics has a ...
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.41, marking a +2.85% move from the previous day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly so...
2 Growth Stocks to Invest $1,000 in Right Now
A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion.
1 Bold Prediction for Viking Therapeutics in 2026
Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.
2 Monster Stocks in the Making to Buy and Hold
CRISPR Therapeutics and Viking Therapeutics are innovative biotechs with attractive pipelines. Both could see their shares soar as they make consistent clinical and regulatory progress.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $36.15 in the latest trading session, marking a -2.51% move from the prior day.
My Top 10 Stocks to Buy for 2026
Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets.
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026
The best-performing stock on this list is up just 4% this year. Investors may be undervaluing these companies' growth opportunities.
Looking At Viking Therapeutics's Recent Unusual Options Activity
High-rolling investors have positioned themselves bullish on Viking Therapeutics (NASDAQ: VKTX), and it's important for retail traders to take note. \This activity came to our attention today through...
Viking Therapeutics: Prepping For A Critical 2026
What's Up With The Jump In Viking Therapeutics Stock?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The ... Full story available on Benzinga.com
Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics
Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study.
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analy...
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029
Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon
If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl...
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.